<DOC>
	<DOC>NCT01224717</DOC>
	<brief_summary>This study is designed to provide information about the bone-anabolic response of PTH134 when administered orally, in comparison to ForsteoÂ®, the sub-cutaneous form of teriparatide, the active ingredient in PTH134.</brief_summary>
	<brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Postmenopausal women osteoporotic/osteopenic with an additional risk factor 45 to 80 years old Use of estrogen or hormone replacement therapy Use of parathormone or parathormone fragments, calcitonin, aluminum supplements, within 12 months prior to first dose. Use of bisphosphonates and strontium ranelate Cancer or history of malignancy of any organ system Any radiation therapy to the skeleton. Any known clinically significant disease affecting calcium metabolism. Any history of metabolic disorders including Paget's disease, osteogenesis imperfecta, or osteomalacia. History or clinical evidence of any impairment of thyroid function Other protocoldefined inclusion/exclusion criteria apply.</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Osteoporosis</keyword>
</DOC>